Can Treg therapy prevent GVHD?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Modulation of Gut Microbiota Through Dietary Fibers to Enhance Regulatory T Cell-Based Immunotherapy in GVHD Following Hematopoietic Stem Cell Transplantation.Nutrients · 2026
   Review
2. Cell-Penetrating Anti-Protein Kinase C Theta Antibodies Act Intracellularly to Generate Stable, Highly Suppressive Regulatory T Cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2020
   Article
3. T cell metabolism in graft-versus-host disease.Blood science (Baltimore, Md.) · 2020
   Review
4. Therapeutic use of regulatory T cells for graft-versus-host disease.British journal of haematology · 2019
   Review
5. Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models.JCI insight · 2018
   Article
6. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.Journal of translational medicine · 2017
   Article
7. Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation.The Journal of clinical investigation · 2016
   Article
8. Treatment of graft-versus-host disease with naturally occurring T regulatory cells.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2013
   Review
9. Adenosine A₂A receptor agonist-mediated increase in donor-derived regulatory T cells suppresses development of graft-versus-host disease.Journal of immunology (Baltimore, Md. : 1950) · 2013
   Article

Corrections and comments

• Comment on
  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.2011

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.